当前位置: X-MOL 学术J. Clin. Lipidol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
JCL roundtable-Lipoprotein(a): The emerging risk factor.
Journal of Clinical Lipidology ( IF 4.4 ) Pub Date : 2018-12-10 , DOI: 10.1016/j.jacl.2018.11.003
Santica M Marcovina 1 , Patrick M Moriarty 2 , Marlys L Koschinsky 3 , John R Guyton 4
Affiliation  

Lipoprotein(a), or Lp(a), is a major risk factor for atherothrombotic events along with low-density lipoprotein cholesterol and, inversely, high-density lipoprotein cholesterol. Lp(a) also contributes to the progression of calcific aortic stenosis and to the rare occurrence of arterial thrombotic strokes without atherosclerosis in children and younger women. Much has been learned about the inheritance of Lp(a) levels and the relationship between apolipoprotein(a) structure and function. Recent work suggests an intriguing interaction between oxidized phospholipids on Lp(a) and inflammatory interleukin-1 genotypes. New pharmaceutical approaches with antisense and RNA interference technology may achieve up to 90% lowering of Lp(a). This Roundtable includes practical considerations for clinically measuring and responding to Lp(a) levels.



中文翻译:

JCL圆桌会议脂蛋白(a):新兴的危险因素。

脂蛋白(a)或脂蛋白(a)是与低密度脂蛋白胆固醇以及反之,高密度脂蛋白胆固醇一起形成动脉粥样硬化事件的主要危险因素。Lp(a)也有助于钙化主动脉瓣狭窄的发展,并有助于少发儿童和年轻女性发生动脉血栓性中风而无动脉粥样硬化。关于Lp(a)水平的遗传以及载脂蛋白(a)结构与功能之间的关系已学到很多。最近的工作表明Lp(a)上的氧化磷脂与炎性白介素1基因型之间的有趣相互作用。具有反义和RNA干扰技术的新药物方法可将Lp(a)降低多达90%。该圆桌会议包括临床测量和响应Lp(a)水平的实际考虑。

更新日期:2018-12-10
down
wechat
bug